Fig. 1

Trial Design for PALISADE, ARC004, and ARTEMIS. Symptom data were recorded from the DBPCFCs across three PTAH trials of participants aged 4 to 17 years who received PTAH or placebo. Endpoints that were examined post hoc focused on evaluating freedom from symptoms and the reduction of symptom severity over time. ^aThe maximum single peanut protein dose tested for the primary clinical efficacy endpoint in PALISADE was 1000 mg in Europe (cumulative amount: 2043 mg) and 600 mg in North America (cumulative amount: 1043 mg). ^bFollowing PALISADE, participants treated with PTAH entering ARC004 could be allocated into one of five extended maintenance cohorts. Cohorts 1 and 3A were daily dosing cohorts and are evaluated in this analysis; the nondaily dosing cohorts (2, 3B, 3C) were not included. DBPCFC double-blind, placebo-controlled food challenge, PTAH peanut (Arachis hypogaea) allergen powder-dnfp